Last reviewed · How we verify
Envafolimab plus Gemcitabine&Cisplatin
Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses.
Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses. Used for Advanced solid tumors.
At a glance
| Generic name | Envafolimab plus Gemcitabine&Cisplatin |
|---|---|
| Sponsor | 3D Medicines (Sichuan) Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Envafolimab specifically targets the PD-1 receptor on T-cells, preventing the binding of PD-L1 and PD-L2, which are often overexpressed on tumor cells. This inhibition leads to enhanced T-cell activation and proliferation, promoting an immune response against cancer cells.
Approved indications
- Advanced solid tumors
Common side effects
- Fatigue
- Rash
- Diarrhea
Key clinical trials
- Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers (PHASE2)
- Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. (PHASE2)
- Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer (PHASE2)
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (PHASE2)
- Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: